Bone Biologics Corporation (BBLGW)
| Market Cap | 1.67M -26.9% |
| Revenue (ttm) | n/a |
| Net Income | -2.86M |
| EPS | -1.92 |
| Shares Out | 1.80M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 118 |
| Open | 3.500 |
| Previous Close | 7.700 |
| Day's Range | 3.500 - 3.500 |
| 52-Week Range | 3.500 - 35.950 |
| Beta | 0.53 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 12, 2026 |
About BBLGW
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or b... [Read more]
News
Bone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 Priorities
BURLINGTON, Mass, July 23, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) ("Bone Biologics" or the "Company"), a developer of orthobiologic products for spine fusion markets...
Bone Biologics files to sell 6.46M shares of common stock for holders
17:15 EDT Bone Biologics (BBLG) files to sell 6.46M shares of common stock for holders
Bone Biologics prices $9.0M offering at $1.42 per share.
Bone Biologics (BBLG) announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale of an aggregate of 2,112,677 shares of...
Bone Biologics Announces up to $9.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
$3.0 million upfront with up to approximately $6.0 million of potential additional gross proceeds upon the exercise in full of warrants in cash $3.0 million upfront with up to approximately $6.0 milli...
Bone Biologics achieves 29-month shelf life for rhNELL-1
Bone Biologics (BBLG) announced that the validated shelf life of its rhNELL-1 protein product has been further extended to 29 months, building on the 24-month milestone the company reported in…
Bone Biologics Achieves 29-Month Validated Shelf Life for rhNELL-1
BURLINGTON, Mass, May 19, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets,...
Bone Biologics summarizes key milestones achieved during 2025
Bone Biologics (BBLG) summarized key corporate, scientific, and operational milestones achieved during 2025 and outlined its strategic outlook for 2026. 2025 Highlights: Extended rhNELL-1 Product Shel...
Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook
Key accomplishments include expanded rhNELL-1 shelf life, advanced NB1 development, strengthened balance sheet, and maintained Nasdaq compliance Key accomplishments include expanded rhNELL-1 shelf lif...
Bone Biologics receives confirmation rhNELL-1 shelf life extended to 24 months
Bone Biologics (BBLG) announces it has received confirmation that the shelf life of its rhNELL-1 product has been extended to 24 months, delivering on previously communicated forecasts. “The extended ...
Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months
Milestone advances manufacturing readiness and supports long-term commercialization strategy Milestone advances manufacturing readiness and supports long-term commercialization strategy
Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that...
Bone Biologics to Participate in the H.C. Wainwright Global Investment Conference
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that...
Bone Biologics Announces Closing of $5.0 Million Public Offering
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announce...
Bone Biologics Announces Pricing of $5.0 Million Public Offering
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announce...
Why Is Bone Biologics Stock (BBLG) Up 100% Today?
Bone Biologics stock rocketed higher on Friday after it filed a patent application for a spinal fusion product.
Bone Biologics files NELL-1 protein patent application with USPTO
Bone Biologics (BBLG) announces the filing of a patent application with the United States Patent and Trademark Office for its novel NELL-1 protein. The patent application is directed to compositions…
Bone Biologics Files Patent Application for Bone Regeneration Technology
BURLINGTON, Mass.--(BUSINESS WIRE)---- $BBLG #Bonebiologics--Bone Biologics files U.S. patent application for bone regeneration technology.
Bone Biologics regains compliance with Nasdaq listing
Bone Biologics (BBLG) “announced that it has received notice from The Nasdaq Stock Market informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq…
Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announce...
Bone Biologics files $35M mixed securities shelf
17:00 EDT Bone Biologics (BBLG) files $35M mixed securities shelf
Bone Biologics Corp trading halted, news pending
19:50 EDT Bone Biologics (BBLG) Corp trading halted, news pending
Bone Biologics announces 1-for-6 reverse stock split
Bone Biologics announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-6. The reverse stock split will take effect as of 12:01 a.m.
Bone Biologics Announces 1-for-6 Reverse Stock Split
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announce...
Bone Biologics Appoints Phillip T. Meikle to its Board of Directors
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces the ...
Bone Biologics Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that...